WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407192
CAS#: 955977-50-1
Description: PI3065 is a p110δ isoform of phosphoinositide-3-OH kinase (PI(3)K) inhibitor. Inhibitors against the p110δ isoform of phosphoinositide-3-OH kinase (PI(3)K) have shown remarkable therapeutic efficacy in some human leukaemias. As p110δ is primarily expressed in leukocytes, drugs against p110δ have not been considered for the treatment of solid tumours. p110δ inactivation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression. p110δ inhibitors can break tumour-induced immune tolerance and should be considered for wider use in oncology
MedKoo Cat#: 407192
Name: PI-3065
CAS#: 955977-50-1
Chemical Formula: C27H31FN6OS
Exact Mass: 506.22641
Molecular Weight: 506.64
Elemental Analysis: C, 64.01; H, 6.17; F, 3.75; N, 16.59; O, 3.16; S, 6.33
PI-3065, purity > 98%, is in stock. The same day shipping out after order is received.
Synonym: PI-3065; PI3065; PI 3065.
IUPAC/Chemical Name: 6-[[4-(Cyclopropylmethyl)-1-piperazinyl]methyl]-2-(5-fluoro-1H-indol-4-yl)-4-(4-morpholinyl)-thieno[3,2-d]pyrimidine
InChi Key: YDNOHCOYQVZOMC-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H31FN6OS/c28-21-3-4-22-20(5-6-29-22)24(21)26-30-23-15-19(17-33-9-7-32(8-10-33)16-18-1-2-18)36-25(23)27(31-26)34-11-13-35-14-12-34/h3-6,15,18,29H,1-2,7-14,16-17H2
SMILES Code: FC1=C(C2=NC(N3CCOCC3)=C4C(C=C(CN5CCN(CC6CC6)CC5)S4)=N2)C7=C(NC=C7)C=C1
The following data is based on the product molecular weight 506.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Ali K, Soond DR, Piñeiro R, Hagemann T, Pearce W, Lim EL, Bouabe H, Scudamore
CL, Hancox T, Maecker H, Friedman L, Turner M, Okkenhaug K, Vanhaesebroeck B.
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance
to cancer. Nature. 2014 Jun 19;510(7505):407-11. doi: 10.1038/nature13444. Epub
2014 Jun 11. PubMed PMID: 24919154; PubMed Central PMCID: PMC4501086.